# Imunon

Source: https://onco.cc/companies/imunon/  
OnCo record `imunon` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Imunon, formerly Celsion, is a New Jersey company developing a DNA-based interleukin-12 immunotherapy for ovarian cancer after its heat-activated liposomal doxorubicin, ThermoDox, failed in liver cancer.

## Summary

Imunon, which renamed itself from Celsion Corporation in 2022, is listed on Nasdaq. Its earlier lead product ThermoDox, a heat-sensitive liposomal doxorubicin released by radiofrequency ablation, failed the phase 3 HEAT and OPTIMA trials in hepatocellular carcinoma. The company now develops IMNN-001 (formerly GEN-1), a plasmid encoding interleukin-12 delivered into the abdomen to treat advanced ovarian cancer alongside chemotherapy, which is in phase 3. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: IMUNON, Inc.; Celsion Corporation; Celsion
- Tags: ctgov-sponsor
- HQ: Lawrenceville, NJ
- Type: biotech
- Website: https://www.imunon.com

## Sources

- Official website: https://www.imunon.com
- ClinicalTrials.gov: trials led by Imunon: https://clinicaltrials.gov/search?lead=Imunon
- Wikipedia: https://en.wikipedia.org/wiki/Celsion_Corporation

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- trials: [Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat](https://onco.cc/trials/nct06915025/), [Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer](https://onco.cc/trials/nct05739981/), [Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)](https://onco.cc/trials/nct03393884/)

---
JSON: https://onco.cc/api/v1/entities/imunon.json